SPX3,647.29-7.75 -0.21%
DIA291.30-1.42 -0.49%
IXIC10,829.50+26.58 0.25%

Larimar Gets FDA Clearance to Start 25 Mg Cohort of Mid-Stage Study of CTI-1601 in Friedreich's Ataxia Patients

Larimar Gets FDA Clearance to Start 25 Mg Cohort of Mid-Stage Study of CTI-1601 in Friedreich's Ataxia Patients

MT Newswires · 09/14/2022 03:48

Please log in to view news